Article

B+L receives approvals

B+L has received FDA approval for bromfenac ophthalmic solution eye drops (Prolensa), CE mark for the Victus femtosecond laser platform for creation of corneal incisions in cataract surgery, and recommendation of approval for the Trulign Toric posterior chamber IOL.

 

Rochester, NY-Bausch + Lomb (B+L) announces that the FDA has approved the company’s new drug application (NDA) for bromfenac ophthalmic solution 0.07% prescription eye drops (Prolensa), a once-daily nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The solution will be available in 1.6-ml and 3-ml bottle sizes.

The solution provides powerful and rapid resolution of inflammation and pain by leveraging the potency of the bromfenac molecule in a formulation designed to facilitate ocular penetration. The formulation allows for a lower concentration of bromfenac in a once-daily dosing regimen. The solution also does not require shaking to deliver a consistent dose in each drop.

In other news from B+L, the Victus femtosecond laser platform has received the CE mark in the European Union for the creation of corneal incisions in patients undergoing cataract surgery, as well as for penetrating keratoplasty and the creation of intrastromal channel incisions for intracorneal ring segments. The platform, offered by B+L Technolas, now has CE mark for all critical steps of laser-assisted cataract surgery, including capsulotomy, lens fragmentation, and corneal incisions.

An FDA advisory panel has recommend approval of B+L’s Trulign Toric posterior chamber IOL for patients who have had a cataract removed and would like to, without glasses, have improved distance vision and reduced residual refractive cylinder.

The toric lens is intended for implantation in the capsular bag of the eye in adult patients to correct aphakia and postoperative refractive astigmatism, according to the FDA.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.